Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review

Kelly Torosian; Esha Lal; Arthur Kavanaugh; Rohit Loomba; Veeral Ajmera; Monica Guma

doi:10.1016/j.semarthrit.2023.152165

Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review

Semin Arthritis Rheum. 2023 Apr:59:152165. doi: 10.1016/j.semarthrit.2023.152165. Epub 2023 Jan 18.

Authors

Kelly Torosian¹, Esha Lal¹, Arthur Kavanaugh², Rohit Loomba³, Veeral Ajmera⁴, Monica Guma⁵

Affiliations

¹ Department of Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.
² Department of Rheumatology, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.
³ Division of Gastroenterology and Hepatology, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA; NAFLD Research Center, Department of Medicine, University of California at San Diego, La Jolla, USA; Division of Epidemiology, Department of Family and Preventative Medicine, University of California at San Diego, La Jolla, USA.
⁴ Division of Gastroenterology and Hepatology, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA; NAFLD Research Center, Department of Medicine, University of California at San Diego, La Jolla, USA. Electronic address: v1ajmera@health.ucsd.edu.
⁵ Department of Rheumatology, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA; Department of Medicine, Autonomous University of Barcelona, Plaça Cívica, 08193 Bellaterra, Barcelona, Spain; San Diego VA Healthcare Service, San Diego, CA, 92161, USA. Electronic address: mguma@health.ucsd.edu.

Abstract

Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share disease pathways given the numerous inflammatory pathways involved in both diseases and a higher prevalence of NAFLD in PD patients. Metabolic syndrome and obesity are a key link between the two diseases, but even when controlling for this, associations between both diseases are still seen. Therapeutics that impact metabolic or inflammatory pathways may be impactful in both PD and NAFLD. In this review, we describe common inflammatory pathways contributing to both PD and NAFLD and critically review the potential impact of treatments for and on both diseases.

Keywords: Inflammatory pathways; Insulin resistance; Non-alcoholic fatty liver disease; Pathogenesis; Psoriatic disease.

Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding